SCHEMBL935201

SCHEMBL935201

Nc1nc(-c2ccccn2)cc2cc(F)ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 3/20 0.44
CCR5 P51681 3/20 0.44
CCR8 P51685 3/20 0.44
METAP1 P53582 2/20 0.43
METAP2 P50579 1/20 0.43
CBFB Q13951 1/20 0.43
KDM4E B2RXH2 5/20 0.42
LMNA P02545 2/20 0.42
POLB P06746 2/20 0.42
CYP1A2 P05177 1/20 0.42
BLM P54132 1/20 0.42
HIF1A Q16665 1/20 0.42
DOHH Q9BU89 1/20 0.42
P4HTM Q9NXG6 1/20 0.42
L3MBTL1 Q9Y468 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALOX15 P16050 2/20 0.42
HSP90AA1 P07900 2/20 0.42
HTT P42858 2/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10389484 0.82 ADORA3 (0.55) CCR1CCR5CCR8METAP1KDM4E
SCHEMBL935711 0.82 CCR1 (0.56) CCR1CCR5CCR8METAP1METAP2
Hydrochloric Acid SCHEMBL11361908 0.81 CCR1 (0.42) CCR1CCR5CCR8METAP1KDM4E
Hydrochloric Acid SCHEMBL11370119 0.81 CCR1 (0.54) CCR1CCR5CCR8METAP1METAP2
SCHEMBL11367963 0.77 CCR1 (0.45) CCR1CCR5CCR8METAP1METAP2
SCHEMBL935285 0.76 MEN1 (0.57) METAP1KDM4ELMNAL3MBTL1SMN1; SMN2
SCHEMBL7549266 0.76 CCR1 (0.64) CCR1CCR5CCR8METAP1METAP2
SCHEMBL8221653 0.75 CCR1 (0.42) CCR1CCR5CCR8METAP1KDM4E
SCHEMBL11381433 0.74 SYK (0.58) CCR1CCR5CCR8METAP1KDM4E
SCHEMBL11371057 0.74 KDM4E (0.49) CCR1CCR5CCR8METAP1METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011006536-A1 PYRIDYL-SUBSTITUTED ISOQUINOLINE DERIVATIVES WITH ACTIVITY AGAINSTMYCOBACTERIAAND ESPECIALLY MYOBACTERIUM TUBERCULOSIS DAFRA PHARMA N.V. (BE) 2011-01-20 WO disclosed